Congratulations to our Senior Vice President of Medical Affairs, Mary Pinder-Schenck, MD for being named to PharmaVoice's 100 list in the life-sciences space! Mary's expertise in oncology patient care, clinical research, and medical affairs is instrumental in our pursuit to deliver innovative, targeted medicines for patients living with cancer. Join us in celebrating Mary's dedication to science and the remarkable recognition of her work. We're excited to see what the future holds under her visionary leadership! https://lnkd.in/e9pFrenZ #PV100 #LifeSciences #Pharma #PharmaVoice100 #PharmaLead
Revolution Medicines
Biotechnology Research
Redwood City, California 16,695 followers
Translating Frontier Oncology Targets to Outsmart Cancer
About us
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
- Website
-
http://www.revmed.com
External link for Revolution Medicines
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
Get directions
700 Saginaw Dr.,
Redwood City, California 94063, US
Employees at Revolution Medicines
Updates
-
In today’s late-breaking session at the EORTC-NCI-AACR Symposium in Barcelona, we shared preliminary data from our Phase 1 study in patients with KRAS G12D pancreatic ductal adenocarcinoma. Read the news in our recent press announcement: https://lnkd.in/gBtrHepA #ENASymp24 #Oncology #PancreaticCancer
-
-
We’re excited to announce updated results from our Phase 1 study in patients living with RAS-mutated pancreatic ductal adenocarcinoma. These data were presented during a late-breaking poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Read the latest here: https://lnkd.in/gp_yA-HY #ENASymp24 #Oncology #PancreaticCancer
-
-
Today we announced a significant milestone as the first patient has been dosed in RASolute 302, our first registrational Phase 3 study in second-line metastatic pancreatic ductal adenocarcinoma (PDAC). https://lnkd.in/gb7Z4HSY #FirstPatient #ClinicalTrials #Oncology #PancreaticCancer
-